No profile data available.
CytoDyn Inc. (CYDY) is a healthcare company in the additional cancer treatment drugs industry, based in Vancouver, United States, with about 14 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of $2.26 million. In Q3 2026 (the quarter ended February 28, 2026) revenue was $0. Its market capitalization was $293.90 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended May 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19.
CytoDyn reported $0 in revenue for fiscal year 2025. In Q3 2026 revenue was $0.
$293.90 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Allogene Therapeutics, Inc. (ALLO), Prelude Therapeutics Incorporated (PRLD), Perspective Therapeutics, Inc. (CATX), Northwest Biotherapeutics, Inc. (NWBO).